Literature DB >> 22445792

HLA antigen expression in melanocytic lesions: is acquisition of HLA antigen expression a biomarker of atypical (dysplastic) melanocytes?

Michael Campoli1, James E Fitzpatrick, Whitney High, Soldano Ferrone.   

Abstract

BACKGROUND: Although criteria are established for the histologic diagnosis of atypical nevi (AN), consensus about the criteria in the diagnosis of and in the definition of AN is limited. Moreover, intraobserver and interobserver differences in the application of these criteria for the diagnosis of AN have been observed.
OBJECTIVE: We sought to determine the usefulness of HLA antigen expression as a biomarker of AN.
METHODS: The immunoperoxidase reaction was used to mark common nevi and AN with HLA class I heavy chain-, β2microglobulin (β2m)-, and HLA class II β chain-specific monoclonal antibodies.
RESULTS: HLA class I heavy chain, β2m, and HLA class II β chain were expressed in 5 (8.6%) of the 58 common nevi and in 46 (∼72%) of the 64 atypical melanocytic lesions. Among common lesions, only halo nevi expressed HLA class I heavy chain, β2m, and HLA class II β chain. The level of HLA class I heavy chain β2m and of HLA class II β chain expression correlated with the degree of cytologic atypia and architectural disorder. LIMITATIONS: The number of lesions tested and the subjective nature of the analysis of immunohistochemical staining of tissue sections are both limitations.
CONCLUSIONS: The data presented suggest that HLA antigen expression is an objective biomarker that correlates well with the degree of cytologic atypia in AN and may: (1) be useful to distinguish common nevi from AN, and (2) represent a more objective measure to determine which AN should be excised.
Copyright © 2011 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22445792     DOI: 10.1016/j.jaad.2011.04.025

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  6 in total

Review 1.  [Dysplastic melanocytic nevus].

Authors:  E Bierhoff
Journal:  Pathologe       Date:  2015-02       Impact factor: 1.011

Review 2.  HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition.

Authors:  Michael Campoli; Soldano Ferrone
Journal:  Semin Immunopathol       Date:  2011-04-28       Impact factor: 9.623

3.  Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.

Authors:  Jennifer Nguyen; Richard Bernert; Kevin In; Paul Kang; Noemi Sebastiao; Chengcheng Hu; K Taraszka Hastings
Journal:  Melanoma Res       Date:  2016-04       Impact factor: 3.599

Review 4.  Introduction: MHC/KIR and governance of specificity.

Authors:  Adrian Kelly; John Trowsdale
Journal:  Immunogenetics       Date:  2017-07-10       Impact factor: 2.846

5.  Oncogene-Expressing Senescent Melanocytes Up-Regulate MHC Class II, a Candidate Melanoma Suppressor Function.

Authors:  John van Tuyn; Farah Jaber-Hijazi; Douglas MacKenzie; John J Cole; Elizabeth Mann; Jeff S Pawlikowski; Taranjit Singh Rai; David M Nelson; Tony McBryan; Andre Ivanov; Karen Blyth; Hong Wu; Simon Milling; Peter D Adams
Journal:  J Invest Dermatol       Date:  2017-06-22       Impact factor: 8.551

6.  Genome-wide analysis of gene and protein expression of dysplastic naevus cells.

Authors:  Linda Gao; Frans A van Nieuwpoort; Jacoba J Out-Luiting; Paul J Hensbergen; Femke A de Snoo; Wilma Bergman; Remco van Doorn; Nelleke A Gruis
Journal:  J Skin Cancer       Date:  2012-11-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.